Drug Landscape ›
Puri-Nethol ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 15
Most-reported reactions
Abdominal Pain — 3 reports (20%) Intestinal Fistula — 2 reports (13.33%) Intestinal Stenosis — 2 reports (13.33%) Large Intestine Perforation — 2 reports (13.33%) Abdominal Hernia — 1 report (6.67%) Abscess Intestinal — 1 report (6.67%) Anaemia Macrocytic — 1 report (6.67%) Anal Abscess — 1 report (6.67%) Anal Fistula — 1 report (6.67%) Anal Injury — 1 report (6.67%)
Source database →
Puri-Nethol in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Puri-Nethol approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Puri-Nethol in United States?
Kjeld Schmiegelow is the originator. The local marketing authorisation holder may differ — check the official source linked above.